Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2503 |
PAC-1
Procaspase activating compound 1 |
Apoptosis; Caspase; Autophagy | Apoptosis; Autophagy; Proteases/Proteasome |
PAC-1 (Procaspase activating compound 1) 是一种 procaspase-3激活剂,诱导癌细胞凋亡,EC50为 2.08 μM,可用于研究淋巴瘤、黑色素瘤、实体瘤、乳腺癌和胸癌等治疗的试验。 | |||
T78105 |
PAC1R antagonist 1
|
PACAP | GPCR/G Protein |
PAC1R antagonist 1为一种具有口服活性的 PAC1 受体拮抗剂,可抑制由垂体腺苷酸环化酶激活多肽(PACAP)及神经损伤所诱导的异常性疼痛,可用于研究肿瘤和与免疫相关的疾病。 | |||
T18603 | PROTAC BRD4 degrader for PAC-1 | Others | Others |
PROTAC BRD4 degrader for PAC-1 (compound 5) is a chimeric BET degrader GNE-987 conjugated with a disulfide-containing linker[1]. This PROTAC-linker conjugate specifically targets and degrades BRD4, enabling selective proteolysis of PAC-1. | |||
TP1618L |
PACAP-38 (31-38), human, mouse, rat acetate
PACAP-38 (31-38), human, mouse, rat acetate(138764-85-9 Free base) |
PACAP | GPCR/G Protein |
PACAP-38 (31-38), human, mouse, rat acetate 是 PAC1 受体的激活剂。PACAP-38 (31-38), human, mouse, rat acetate 对交感神经元 NPY 和儿茶酚胺的产生具有强效、有效和持续的刺激作用,可用于神经营养和神经保护研究。 | |||
T41005 |
PA-8
|
PACAP | GPCR/G Protein |
PA-8是一种小分子的的 PACAP I 型(PAC1)受体拮抗剂,有 选择性、有效性和口服活性。PA-8抑制PACAP 诱导的CREB 在PAC1-受体上的磷酸化,但对VPAC11或VPAC2受体无抑制作用。PA-8也抑制pacap 诱导的体外cAMP 水平升高(IC50 = 2 nM)和体内鞘内注射后pacap 诱导的厌恶反应和机械异位性痛。 | |||
T76949 | Zelminemab | ||
Zelminemab (AMG-301) 是一种人单克隆抗体,可抑制 I 型 PACAP (PAC1) 受体。 | |||
T29140 |
VU0652925
VU 0652925,BMS-3,VU-0652925,BMS3,BMS 3 |
||
VU0652925 is a PAR4 antagonist. VU0652925 has a P-sel IC50 of 39.2 pM (-pIC50±SEM: 10.41±0.04) and a PAC1 IC50 of 43.0 pM (-pIC50±SEM: 10.4±0.04). | |||
TP2071 |
Bay 55-9837
|
||
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). S | |||
T24585 |
PA-9
PA 9 |
||
PA-9 is the first small-molecule PAC1 receptor antagonist. | |||
T81891 |
M65
|
||
M65为PAC1受体特异性拮抗剂,可抑制ANP释放。 | |||
TP1069 |
PACAP (1-27), human, ovine, rat TFA
PACAP 1-27 TFA |
||
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is an N-terminal fragment of pacap-38 and an effective PACAP receptor antagonist. The IC50s for rat PAC1, rat VPAC1 and human VPAC2 are 3nm, 2nm and 5nm respectively. | |||
T36427 |
PACAP (6-27) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt)
|
PACAP | GPCR/G Protein |
Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, ... | |||
TP1878 |
PACAP (1-38), human, ovine, rat
Pituitary Adenylate Cyclase Activating Polypeptide 38,腺苷酸环化酶激活肽-38(抗原),PACAP 1-38 |
PACAP | GPCR/G Protein |
PACAP (1-38), human, ovine, rat (Pituitary Adenylate Cyclase Activating Polypeptide 38) 是含有 38 个氨基酸残基的神经肽。它能够结合 PACAP I 型受体(IC50:4 nM)、PACAP II 型受体 VIP1(IC50:2 nM)、PACAP II 型受体 VIP2(IC50:1 nM)。 |